Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 4/20 | 0.49 |
| ▸ | CDK2 | P24941 | 4/20 | 0.49 |
| ▸ | CDK7 | P50613 | 4/20 | 0.49 |
| ▸ | CCNH | P51946 | 4/20 | 0.49 |
| ▸ | MNAT1 | P51948 | 4/20 | 0.49 |
| ▸ | CCNK | O75909 | 3/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241795 | 1.00 | CCNA2 (0.49) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL3659905 | 0.91 | KDM4E (0.51) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL8224532 | 0.89 | PDGFRB (0.45) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL8224408 | 0.89 | PDGFRB (0.45) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL4247218 | 0.89 | GFER (0.49) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL4247223 | 0.89 | GFER (0.49) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL4238388 | 0.88 | HCRTR1 (0.49) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL4238382 | 0.88 | HCRTR1 (0.49) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL4245733 | 0.85 | HCRTR1 (0.52) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL4245731 | 0.85 | HCRTR1 (0.52) | CCNA2CDK2CDK7CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | CCNA2 2382/4885CDK2 1457/4885CDK7 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.